Lilly and Boehringer Ingelheim's (BI) Abasaglar is the first biosimilar version of the top-selling insulin analogue to hit western European markets, and could eventually take a sizeable market share.

(Reuters) - Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at a $150 discount to the cost of the injector pen versions ...

Lilly said in a statement that patients could buy the Zepbound vials for $499 per month on its LillyDirect website, roughly 23% cheaper than the $650 it charges for its injector pen to insured ...

Investing.com - Eli Lilly (NYSE:LLY) announced on Tuesday that it would begin selling 7.5 milligram and 10 milligram single-dose vials of its Zepbound weight-loss drug at a roughly $150 discount to ...